A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Assess the Efficacy, Safety and Tolerability of Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Intensive Phase Therapy of Melioidosis in Hospitalized Patients
Latest Information Update: 21 Feb 2024
At a glance
- Drugs Ceftazidime (Primary) ; Fusidic acid (Primary) ; Meropenem (Primary)
- Indications Burkholderia infections; Melioidosis
- Focus Adverse reactions
- Acronyms TERRA
- Sponsors Aceragen; Arrevus
- 14 Feb 2024 Status changed from recruiting to completed.
- 04 Aug 2023 Planned End Date changed from 1 Jan 2023 to 1 Nov 2023.
- 04 Aug 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Sep 2023.